Evomet leverages basic research to impact drug development and the clinical standard of care. Cancer incidence is growing alarmingly, with currently more than 3,5 million people affected by it in Europe. Metastasis causes the vast majority of cancer-related deaths. It is usually resistant to conventional therapies and can lead to the failure of vital organs. Additionally, research on the evolution of metastases, from their establishment to treatment resistance, has so far been limited. It uses a multidisciplinary array of training initiatives and techniques that integrate cutting-edge genomic, single-cell omics, and in vivo validation strategies. Evomet’s function-centric approach to studying the metastasis process can potentially change how cancer metastasis is understood and reveal actionable therapeutic targets.
